testosterone enanthate injection — CareFirst (Caremark)

Initial criteria

• The requested drug is NOT being prescribed for age-related hypogonadism (also referred to as late-onset hypogonadism).
• The patient’s comorbid conditions are reasonably controlled.
• The patient has been educated on ANY contraindications AND side effects to therapy.
• Before the start of therapy, the patient has been informed of fertility preservation options.
• If the patient is less than 18 years of age, then ALL of the following criteria are met:
• The requested drug is prescribed by, or in consultation with, a provider specialized in the care of transgender youth (e.g., pediatric endocrinologist, family or internal medicine physician, obstetrician-gynecologist), that has collaborated care with a mental health provider.
• The patient has reached, or has previously reached, Tanner stage 2 of puberty or greater.

Reauthorization criteria

• All patients requesting authorization for continuation of therapy must meet all requirements in the coverage criteria section.

Approval duration

36 months